title: Possible estuary-associated syndrome: symptoms, vision, and treatment.
abstract: The human illness designated as possible estuarine-associated syndrome (PEAS) by the Centers for Disease Control and Prevention (CDC) has been associated with exposure to estuaries inhabited by toxin-forming dinoflagellates, including members of the fish-killing toxic Pfiesteria complex (TPC), Pfiesteria piscicida and Pfiesteria shumwayae. Humans may be exposed through direct contact with estuarine water or by inhalation of aerosolized or volatilized toxin(s). The five cases reported here demonstrate the full spectrum of symptoms experienced during acute and chronic stages of this suspected neurotoxin-mediated illness. The nonspecific symptoms most commonly reported are cough, secretory diarrhea, headache, fatigue, memory impairment, rash, difficulty in concentrating, light sensitivity, burning skin upon water contact, muscle ache, and abdominal pain. Less frequently encountered symptoms are upper airway obstruction, shortness of breath, confusion, red or tearing eyes, weakness, and vertigo. Some patients experience as few as four of these symptoms. The discovery that an indicator of visual pattern-detection ability, visual contrast sensitivity (VCS), is sharply reduced in affected individuals has provided an objective indicator that is useful in diagnosing and monitoring PEAS. VCS deficits are present in both acute and chronic PEAS, and VCS recovers during cholestyramine treatment coincident with symptom abatement. Although PEAS cannot yet be definitively associated with TPC exposure, resolution with cholestyramine treatment suggests a neurotoxin-mediated illness.
authors.affiliation: McCready Outpatient Services Center, Pocomoke City, Maryland, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Shoemaker
authors.forename: H K
authors.initials: HK
authors.lastname: Hudnell
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000982:Antipruritics / Q000627:therapeutic use*; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D002908:Chronic Disease; D004141:Dinoflagellida / Q000472:pathogenicity; D005068:Eutrophication; D005260:Female; D005399:Fishes / Q000469:parasitology*; D006801:Humans; D008297:Male; D008387:Marine Toxins / Q000009:adverse effects*; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D020045:Pfiesteria piscicida / Q000472:pathogenicity; D011528:Protozoan Infections / Q000175:diagnosis* / Q000209:etiology; D012871:Skin Diseases / Q000188:drug therapy / Q000469:parasitology; D014786:Vision Disorders / Q000209:etiology*; D014787:Vision Tests; D014792:Visual Acuity / Q000187:drug effects; D014867:Water / Q000469:parasitology; D014876:Water Pollution
chemical_list: D000982:Antipruritics; D008387:Marine Toxins; D014867:Water; D002792:Cholestyramine Resin